17   References

  1. Fleeger CA (ed). USAN and the USP Dictionary of Drug Names. USP Convention Inc. 1993 (Rockville)
  2. McEnvoy GK (ed). AHFS Drug Information. ASHP Inc. 1993 (Bethesda)
  3. Bem JL, Peck R. Dextromethorphan. An overview of safety issues. Drug Saf. 1992;7:190-199.
  4. Murray S, Brewerton T. Abuse of over-the-counter dextromethorphan by teenagers. South. Med. J.. 1993;86:1151-1153.
  5. Schadel M, Romach MK, Sellers EM. Mania and cough syrup [letter]. J. Clin. Psychiatry. 1993;54:200.
  6. Craig DF. Psychosis with Vicks Formula 44-D abuse. Can. Med. Assoc. J.. 1992;146:1199-1200.
  7. Jacobs MR, Fehr KO. Drugs and Drug Abuse. . 1987 (Toronto)
  8. Dukes, MNG (ed). Meyler's Side Effects of Drugs. Elsevier. 1992 (Amsterdam)
  9. Rammer L, Holmgren P, Sandler H. Fatal intoxication by dextromethorphan: a report on two cases. Forensic Sci. Int.. 1988;37:233-236.
  10. Jacqz-Aigrain E, Cresteil T. Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies. Dev. Pharmacol. & Therapeutics. 1992;18:161-168.
  11. Kerry NL, Somogyi AA, et al. Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark agouti rat liver microsomes. Biochem. Pharmacol.. 1993;45:833-839.
  12. Duche JC, Querol-Ferrer V, et al. Dextromethorphan O- demethylation and dextrorphan glucuronidation in a French population. Int. J. Clin. Pharmacol., Therapy, & Toxicology. 1993;31:392-398.
  13. Irshaid YM, al-Hadidi HF, Raweshdeh NM. Dextromethorphan O- demethylation polymorphism in Jordanians. Eur. J. Clin. Pharmacol.. 1993;45:271-273.
  14. Freche JP, Dragacci S, et al. Development of an ELISA to study the polymorphism of dextromethorphan oxidation in a French population. Eur. J. Clin. Pharmacol. 1990;39:481-485.
  15. Funck-Brentano C, Thomas G, et al. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype, and response to the administration of encainide in humans. J. Pharmacol. & Exp. Therapeutics. 1992;263:780-786.
  16. Mura C, Panserat S, et al. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. Human Gen.. 1993;92:367-372.
  17. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics. 1993;3:197-204.
  18. Evans WE, Relling MV. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics. 1991;1:143-148.
  19. Meldrum BS. Excitatory amino acid receptors and disease. Opin. Neurol. Neurosurg.. 1992;5:508-513.
  20. Radek RJ, Giardina WJ. The neuroprotective effects of dextromethorphan on guinea pig oxygen-derived hippocampal slices during hypoxia. Neurosci. Lett.. 1992;139:191-193.
  21. Steinberg GK, Lo EH, et al. Dextromethorphan alters cerebral blood flow and protects against cerebral injury following focal ischemia. Neurosci. Lett.. 1991;133:225-228.
  22. Steinberg GK, Kunis D, et al. Neuroprotection following focal cerebral ischaemia with the NMDA antagonist dextromethorphan, has a favourable dose response profile. Neurological Res.. 1993;15:174-180.
  23. Panter SS, Faden AI. Pretreatment with NMDA antagonists limits release of excitatory amino acids following traumatic brain injury. Neurosci. Lett.. 1992;136:165-168.
  24. Finnegan KT, Kerr JT, et al. Dextromethorphan protects against the neurotoxic effects of p-chloroamphetamine in rats. Brain Res.. 1991;558:109-111.
  25. Henderson MG, Fuller RW. Dextromethorphan antagonizes the acute depletion of brain serotonin by p-chloroamphetamine and H75/12 in rats. Brain Res.. 1992;594:323-326.
  26. Lancaster FE. Alcohol, nitric oxide, and neurotoxicity: is there a connection? - a review. Alcohol Clin. Exp. Res.. 1992;16:539-541.
  27. Morgan PF. Is quinolinic acid an endogenous excitotoxin in alcohol withdrawal?. Med. Hypotheses. 1991;36:118-121.
  28. Danysz W, Dyr W, et al. The involvement of NMDA receptors in acute and chronic effects of ethanol. Alcohol Clin. Exp. Res. 1992;16:499-504.
  29. Morgan PF, Nadi NS, et al. Mapping rat brain structures activated during ethanol withdrawal: role of glutamate and NMDA receptors. Eur. J. Pharmacol.. 1992;225:217-223.
  30. Heyes MP, Saito K, Markey SP. Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J.. 1992;283(pt 3):633-635.
  31. Heyes MP, Satio K, et al. Poliovirus induces indolamine-2,3-dioxygenase and quinolinic acid synthesis in macaque brain. FASEB-J.. 1992;6:2977-2989.
  32. Loscher W, Honack D. Differences in anticonvulsant potency and adverse effects between dextromethorphan and dextrorphan in amygdala-kindled and non-kindled rats. Eur. J. Pharmacol.. 1993;238:191-200.
  33. Schmitt B, Netzer R, et al. Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients. J. Neurol., Neurosurg. & Psychiatry. 1994;57:333-339.
  34. Koyuncuoglu H, Saydam B. The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine. Int. J. Clin. Pharmacol., Therapy, & Toxicol.. 1990;28:147-152.
  35. Welch L, Sovner R. The treatment of a chronic organic mental disorder with dextromethorphan in a man with severe mental retardation. Br. J. Psychiatry. 1992;161:118-120.
  36. Bonuccelli U, Del Dotto P, et al. Dextromethorphan and parkinsonism [letter]. Lancet.. 1992;340:53.
  37. Chapman V, Dickenson AH. The combination of NMDA antagonism and morphine produces profound antinociception in the rat dorsal horn. Brain Res.. 1992;573:321-323.
  38. Maneckjee R, Minna JD. Biologically active MK-801 and SKF-10,047 binding sites distinct from those in rat brain are expressed on human lung cancer cells. Mol. Biol. Cell.. 1992;3:613-619.
  39. Otton SV, Wu D, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. & Therapeutics. 1993;53:401- 409.
  40. Achamallah NS. Visual hallucinations after combining fluoxetine and dextromethorphan [letter]. Am. J. Psychiatry. 1992;149:1406.
  41. Kintz P, Mangin P. Toxicological findings in a death involving dextromethorphan and terfenadine. Am. J. Forensic Med. Pathol.. 1992;13:351-352.
  42. Kamei J, Iwamoto Y, Misawa M, Kasuya Y. Effects of rimcazole, a specific antagonist of sigma sites, on the antitussive effects of non-narcotic antitussive drugs. Eur. J. Pharmacol.. 1993;242:209-211.
  43. Szekely JI, Sharpe LG, Jaffe JH. Induction of phencyclidine-like behavior in rats by dextrorphan but not dextromethorphan. Pharmacol. Biochem. Behav.. 1991;40:381-386.
  44. Klein M, Musacchi JM. High-affinity dextromethorphan and (+)- 3-(3-hydroxyphenyl)-N-(1-propyl)piperidine binding sites in rat brain. Allosteric effects of ropizine. J. Pharmacol. Exp. Ther.. 1992;260:990-999.
  45. Thompson KW, Westerlain CG. Dextromethorphan and its combination with phenytoin facilitate kindling. Neurology. 1993;43:992-994.
  46. Simpson MD, Slater P, et al. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr. Res.. 1991;6:41- 48.
  47. Lang A, Vasar E, et al. The involvement of sigma and phencyclidine receptors in the action of antipsychotic drugs. Pharmacol. Toxicol.. 1992;71:132-138.
  48. Shibuya H, Mori H, Toru M. Sigma receptors in schizophrenic cerebral cortices. Neurochem. Res.. 1992;17:983-990.
  49. Debonnel G. Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. [Review]. J. Psychiatry & Neurosci.. 1993;18:157-172.
  50. Micheletti G, Lannes B, et al. Chronic administration of NMDA antagonists induces D2 receptor synthesis in rat striatum. Brain. Res. Mol. Brain Res.. 1992;14:362-368.
  51. Wolfe SA Jr, De Souza EB. Sigma and phencyclidine receptors in the brain-endocrine-immune axis. [Review]. NIDA Res. Monograph Ser.. 1993;133:95-123.
  52. Huang X, Nichols DE. 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur. J. Pharmacol.. 1993;238:291-296.
  53. Khanna JM, Shah G, Weiner J, et al. Effect of NMDA receptor antagonists on rapid tolerance to ethanol. Eur. J. Pharmacol.. 1993;230:23-31.
  54. Schneider SM, Michelson EA, et al. Dextromethorphan poisoning reversed by naloxone. [Review]. Am. J. Emerg. Med.. 1991;9:237- 238.
  55. Kamei J, Iwamoto Y, et al. Involvement of haloperidol-sensitive sigma-sites in antitussive effects. Eur. J. Pharmacol.. 1992;224:39-43.
  56. Kamei J, Mori T, et al. Serotonin release in nucleus of the solitary tract and its modulation by antitussive drugs. Res. Commun. Chem. Pathol. Pharmacol.. 1992;76:371-374.
  57. Kamei J, Mori T, et al. Effects of 8-hydroxy-2-(di-n- propylamino)tetralin, a selective agonist of 5-HT1A receptors, on the cough reflex in rats. Eur. J. Pharmacol.. 1991;203:253-258.
  58. Zhou GZ, Musacchio JM. Computer-assisted modeling of multiple dextromethorphan and sigma binding sites in guinea pig brain. Eur. J. Pharmacol.. 1991;206:261-269.
  59. Netzer R, Pflimlin P, Trube G. Dextromethorphan blocks N- methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur. J. Pharmacol.. 1993;238:209-216.
  60. Canoll PD, Smith PR, Musacchio JM. Ropizine concurrently enhances and inhibits [3H]dextromethorphan binding to different structures of the guinea pig brain: autoradiographic evidence for multiple binding sites. Life Sci.. 1990;46:PL9-16.
  61. Weight FF, Aguayo LG, et al. GABA- and glutamate-gated ion channels as molecular sites of alcohol and anesthetic action. Adv. Biochem. Psychopharmacol.. 1992;47:335-347.
  62. Sanna E, Serra M, et al. GABAA and NMDA receptor function during chronic administration of ethanol. Adv. Biochem. Psychopharmacol.. 1992;47:317-324.
  63. Bubser M, Keseberg U, Notz PK, Schmidt WJ. Differential behavioural and neurochemical effects of competitive and non competitive NMDA receptor antagonists in rats. Eur. J. Pharmacol.. 1992;229:75-82.
  64. Oye I, Paulsen O, et al. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. Pharmacol. Exp. Ther.. 1992;260:1209-1213.
  65. Miller CL, Bickford PC, et al. Phencyclidine and auditory sensory gating in the hippocampus of the rat. Neuropharmacology. 1992;31:1041-1048.
  66. Mayer ML, Benveniste M, et al. Pharmacologic properties of NMDA receptors. Ann. N.Y. Acad. Sci.. 1992;648:194-204.
  67. Gasic GP, Heinemann S. Receptors coupled to ionic channels: the glutamate receptor family. Curr. Opin. Neurobiol.. 1991;1:20- 26.
  68. Bortolotto ZA, Collingridge GL. Activation of glutamate metabotropic receptors induces long-term potentiation. Eur. J. Pharmacol.. 1992;214:297-298.
  69. Walker JM, Bowen WD, et al. A comparison of (-)- deoxybenzomorphans devoid of opiate activity with their dextrorotary phenolic counterparts suggests role of sigma-2 receptors in motor function. Eur. J. Pharmacol.. 1993;231:61-68.
  70. Akunne HC, Johannessen JN, et al. MPTP lesions of the nigrostriatal dopaminergic projection decrease [3H]1-[1-(2- thienyl)cyclohexyl)piperidine binding to PCP site 2: further evidence that PCP site 2 is associated with the biogenic amine reuptake complex. Neurochem. Res.. 1992;17:261-264.
  71. Rogers C, Lemaire S. Characterization of [3H]desmethylimipramine binding in bovine adrenal medulla: interactions with sigma- and (or) phencyclidine-receptor ligands. Can. J. Physiol. Pharmacol.. 1992;70:1508-1514.
  72. Izenwasser S, Newman AH, Katz JL. Cocaine and several sigma receptor ligands inhibit dopamine uptake in rat caudate-putamen. Eur. J. Pharmacol.. 1993;243:201-205.
  73. Witkin JM, Terry P, et al. Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl)hexyloxyl-3- methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J. Pharmacol. & Exp. Therapeutics. 1993;266:473-482.
  74. Shirayama Y, Nishikawa T, Umino A, Takahashi K. p-Chlorophenylalanine-reversible reduction of sigma binding sites by chronic imipramine treatment in rat brain. Eur. J. Pharmacol.. 1993;237:117-126.
  75. Massamiri T, Duckles SP. Interactions of sigma and phencyclidine receptor ligands with the norepinephrine uptake carrier in both rat brain and rat tail artery. J. Pharmacol. Exp. Ther.. 1991;256:519-524.
  76. Rao TS, Cler JA, et al. Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma receptor ligand, in vivo. Neuropharmacology. 1991;4:95-102.
  77. Gorski JC, Jones DR, et al. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol.. 1994;48:173-182.
  78. Conner MA, Chavkin C. Ionic zinc may function as an endogenous ligand for the haloperidol-sensitive sigma 2 receptor in rat brain. Mol. Pharmacol.. 1992;42:471-479.
  79. Jeanjean AP, Mestre M, Maloteaux JM, et al. Is the sigma-2 receptor in rat brain related to the K+ channel of class III antiarrhythmic drugs?. Eur J. Pharmacol.. 1993;241:111-116.
  80. Itzhak Y. Repeated methamphetamine-treatment alters brain sigma receptors. Eur. J. Pharmacol. 1993;230:243-244.
  81. Mash DC, Zabetian CF. Sigma receptors are associated with cortical limbic areas in the primate brain. Synapse. 1992;12:195- 205.
  82. Roman FJ, Martin B, Junien JL. In vivo interaction of neuropeptide Y and peptide YY with sigma receptor sites in the mouse brain. Eur. J. Pharmacol.. 1993;242:305-307.
  83. Karbon EW, Enna SJ. Pharmacological characterization of sigma binding sites in guinea pig brain membranes. Adv. Exp. Med. Biol.. 1991;287:51-59.
  84. Klein M, Canoll PD, Musacchio JM. SKF 525-A and cytochrome P-450 ligands inhibit with high affinity the binding of [3H]dextromethorphan and sigma ligands to guinea pig brain. Life Sci.. 1991;48:543-550.
  85. Larson AA, Sun X. Regulation of sigma activity by amine- terminus of substance P in the mouse spinal cord: involvement of phencyclidine (PCP) sites not linked to N-methyl-D-aspartate (NMDA) activity. Neuropharmacology. 1993;32:909-917.
  86. Su TP. Deliniating biochemical and functional properties of sigma receptors: emerging concepts. [Review]. Crit. Rev. in Neurobiol.. 1993;7:187-203.
  87. Beaton JA, Stemsrud K, Monaghan DT. Identification of a novel N-methyl-D-aspartate receptor population in the rat medial thalamus. J. Neurochem.. 1992;59:754-757.
  88. Keller EA, Borghese CM, et al. The learning capacity of high or low performance rats is related to the hippocampus NMDA receptors. Brain Res.. 1992;576:162-164.
  89. Loscher W, Annies R, Honack D. Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats. Eur. J. Pharmacol.. 1993;242:263-274.
  90. Loscher W, Honack D. Effects of the novel 5-HT1A receptor antagonist, (+)-WAY 100135, on the stereotyped behaviour induced by NMDA receptor antagonist dizocilpine in rats. Eur. J. Pharmacol.. 1993;242:99-104.
  91. Brent PJ, Chahl LA, Cantarella PA, Kavanagh C. The kappa- opioid receptor agonist UH50,488H induces acute physical dependence in guinea-pigs. Eur. J. Pharmacol.. 1993;241:149-156.
  92. Grynne BH, Holmen AT, Maurset A. Evidence for distinct phencyclidine and SKF10047 receptors following detergent treatment of rat brain membranes. Pharmacol. Toxicol.. 1992;70:25-30.
  93. Muraki A, Komaya T, et al. MK-801, a non-competative antagonist of NMDA receptor, prevents methamphetamine-induced decrease of striatal dopamine uptake sites in the rat striatum. Neurosci. Lett. 1992;136:39-42.
  94. Simpson MD, Slater P, et al. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Res.. 1992;42:273-282.
  95. Shinn AF (ed). Evaluations of Drug Interactions. Macmillan. 1988 (NY)
  96. Newman AH, Bevan K, et al. Synthesis and Evaluation of 3-Substituted 17-Methylmorphinan Analogs as Potential Anticonvulsant Agents. J. Med. Chem.. 1992;35:4135-4142.
  97. Su, Tsung-Ping. Pharmacologic Characterizations of Sigma Receptors. Sigma, PCP, and NMDA Receptors. 1993:NIDA Research Monograph 133.
  98. Quirion R, DiMaggio DA, et al. Evidence for an endogenous peptide ligand for the phencyclidine receptor. Peptides. 1984;5:967-973.
  99. DiMaggio DA, Contreras PC, et al. Biological and chemical characterization of the endopsychosins: Distinct ligands for PCP and sigma sites. Sigma and Phencyclidine-Like Compounds as Molecular Probes in Biology. NPP Books. 1988 (Ann Arbor)
  100. Rothman SM, Olney JW. Excitotoxicity and the NMDA Receptor - still lethal after eight years. Trends in Neurosci.. 1995;18:57-58.
  101. Vilner et al. Sigma receptor mediated morphologic and cytotoxic effects. J. Neurosci.. 1995;15(1):118-134.
  102. Yamada M, Nishigami T, et al. Relationship between sigma-like site and progesterone-binding site of adult male rat liver microsomes. Hepatology. 1994;Nov:1271-1280.
  103. N/A. Cocaine-sensitive sigma receptor and its interaction with steroid hormones in the human placental syncytiotrophoblast and in choriocarcinoma cells. Endocrinology. 1995;136(3):924-923.
  104. N/A. A role of sigma receptors on hypoxia/hypoglycemia-induced decrease in CA1 presynaptic fiber spikes in rat hippocampal slices. Brain Res.. 1995;670(2):337-341.
  105. N/A. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res.. 1995;55(2):408-413.
  106. N/A. The sigma-selective ligand NE-100 attenuates the effect of phencyclidine in a rat diving model. Gen. Pharmacol.. 1995;26(1):177-182.
  107. N/A. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced cognitive dysfunction. Eur. J. Pharmacol. 1994;263(1 part 2):9-15.
  108. N/A. Sigma receptor mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res.. 1995;671(1):45-53.
  109. N/A. Altered N-methyl-D-aspartate (NMDA) activity in the mouse spinal cord following morphine is mediated by sigma activity. Brain Res.. 1995;672(1 part 2):83-88.
  110. N/A. The role of NMDA and sigma systems in the behavioral effects of phencyclidine in preweanling rats. Neurotoxicol.. 1994;15(1):191-200.
  111. N/A. Substance P analogs displace sigma binding differentially in the brain and spinal cord of the adult mouse. Metabol. Brain Diseases. 1994;9(3):249-255.
  112. N/A. Sigma-receptor regulation of [3H]arachidonic acid release from rat neonatal cerebellar granule cells in culture. J. Neurochem. 1994;63(4):1311-1318.
  113. N/A. Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands. J. Pharmacol & Exp. Therapeutics. 1994;271(1):212-220.
  114. N/A. Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor. J. Medicinal Chem.. 1994;37(24):4109-4117.
  115. N/A. Discriminative stimulus effects of dextromethorphan in rats. Psychopharmacol.. 1994;116(3):249-254.
  116. Behavioral evidence for a modulating role of sigma ligands in memory process. I. Attenuation of dizocilpine (MK-801)-induced amnesia. Brain Res.. 1994;647(1):44-56.
  117. Behavioral evidence for a modulating role of sigma ligands in memory process. II. Reversion of carbon monoxide-induced amnesia. Brain Res. 1994;647(1):57-64.
  118. Chein CC, Pasternak GW. Functional antagonism of morphine analgesia by (+)-pentazocine: evidence for an anti-opioid sigma 1 system. Eur. J. Pharmacol. 1993;250(1):R7-R8.
  119. Jansen KL, Faull RL, et al. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. Brain Res. . 1993;632(2):299-302.
  120. N/A. Pharmacological characteristics of hyperambulation induced by the sigma ligand (+)-3-PPP in rats. Japanese J. Pharmacol.. 1994;65(1):1-7.
  121. N/A. 4-Methoxyphenyl 4-(3,4,5-trimethoxybenzyl)-1-piperazineacetate monofumarate monohydrate (KB-5492), a new anti-ulcer agent with a selective affinity for the sigma receptor, prevents cysteamine-induced duodenal ulcers in rats by a mechanism different from that of cimetidine. Japanese J. Pharmacol. 1994;64(3):221-224.
  122. N/A. Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds. J. Medicinal Chem. 1994;37(13):1964-1970.
  123. N/A. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J. Pharmacol. 1994;268(1):9-18.
  124. N/A. Sigma receptor ligands modulate contractility, Ca2+ influx and beating rate in cultured cardiac myocytes. J. Pharmacol & Exp. Therapeutics. 1994;269(3):1300-1309.
  125. N/A. Modulation of the PCP/NMDA receptor complex and sigma binding sites by psychostimulants. Neurotoxicol. & Teratol.. 1994;16(4):363-368.
  126. N/A. PCP Site 2: a high affinity MK-801-insensitive phencyclidine binding site. Neurotoxicol & Teratol. 1994;16(4):343-53.
  127. N/A. Novel 1-phenylcycloalkanecarboxylic acid derivatives are potent and selective sigma 1 ligands. J Medicinal Chem. 1994;;37(15):2285-2291.
  128. N/A. SKF-10,047 reverses stress-induced motor suppression: interaction with dopaminergic system. Eur J Pharmacol. 1994;260(1):39-46.
  129. N/A. Sigma-1 and sigma-2 sites in rat brain: comparison of regional, ontogenetic, and subcellular patterns. Synapse. 1994;17(3):182-189.
  130. N/A. Ameliorating effects of sigma receptor ligands on the impairment of passive avoidance tasks in mice: involvement in the central acetylcholinergic system. Eur J Pharmacol. 1994;261(1-2):43-51.
  131. N/A. Low dose of 1,3-di(2-tolyl)guanidine (DTG) attenuates MK-801 induced spatial working memory impairment in mice. Psychopharmacol. 1994;114(3):520-522.
  132. N/A. Massive dextromethorphan ingestion and abuse. Am J. Emerg. Med. 1995;13(2):174-176.
  133. N/A. The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. Int. J Clin Pharmacol & Therapeutics. 1995;33(1):13-19.
  134. N/A. Neuroprotection by N-methyl-D-aspartate antagonists in focal cerebral ischemia is dependent on continued maintenance dosing. Neuroscience. 1995;;64(1):99-107.
  135. Näkki R, Koistinaho J, et al. Cerebellar toxicity of phencyclidine. J. Neurosci.. 1995;15(3):2097-2108.
  136. Hinsberger A, Sharma V, Mazimian D. Cognitive deterioration from long-term abuse of dextromethorphan: a case report. J. Psychiatry & Neurosci.. 1994;19(5):375-377.
  137. Hofstadter DR. Gödel, Escher, Bach: an eternal golden braid. Basic Books;. 1979 (New York)
  138. Itzhak Y (editor). Sigma receptors. Academic Press;. 1994 (San Diego)
  139. McElwee NE, Veltri JC. Intentional abuse of dextromethorphan (DM) products: 1985 to 1988 statewide data. Vet. Hum. Toxicol.. 1990;32:355.
  140. Fleming PM. Dependence on dextromethorphan hydrobromide. BMJ. 1986;293:597.
  141. Helfer J, Kim OM. Psychoactive abuse potential of Robitussin DM. Am. J. Psychiatry. 1990;147:5.
  142. Fisher R, Cysyk B, et al. Dextromethorphan for treatment of complex partial seizures. Neurology. 1990;40:547-549.
  143. Delvin KM, Hall AH, Smolinske SC, et al. Toxicity from long-lasting dextromethorphan preparations. Vet. Hum. Toxicol.. 1985;28:296.
  144. Ng YY, Lin WL, et al. Spurious hyperchloremia and decreased anion gap in a patient with dextromethorphan bromide. Am J Nephrol. 1992;12:268-70.
  145. Baldwin SJ, Bloomer JC, et al. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica. 1995;25(3):261-70.
  146. Yun CH, Jeong HG, et al. Non-specific inhibition of cytochrome P450 activities by chlorphyllin in human and rat liver microsomes. Carcinogenesis. 1995;16(6):1437-40.
  147. Gram LF, Guentert TW, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol & Ther. 1995;57(6):670-7.
  148. Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism & Disposition. 1995;23(1):154-8.
  149. Kimonen T, Juvonen RO, et al. The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br J Pharmacol. 1995;114(4):832-6.
  150. Hiratsuka A, Chu TY, et al. Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat. Drug Metabolism & Disposition. 1995;23(2):201-6.
  151. Hiroi T, Ohishi N, et al. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. J Pharmacol & Exp Therapeutics. 1995;272(2):939-44.
  152. von Moltke LL, Greenblatt DJ, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol. 1995;15(2):125-31.
  153. Lee HS, Jin C, et al. Modulation of cytochrome P450 activities by 7,8-benzoflavone and its metabolites. Biochem & Mol Bio Int. 1994;34(3):483-91.
  154. Ronis MJ, Ingelman-Sundberg M, Badger TM. Induction, suppression and inhibition of multiple hepatic cytochrome P450 isozymes in the male rat and bobwhite quail (Colinus virginianus) by ergosterol biosynthesis inhibiting fungicides (EBIFs). Biochem Pharmacol. 1994;48(10):1953-65.
  155. Jerling M, Merle Y, et al. Population pharmacokinetics of nortiptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 -- an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol. 1994;38(5):453-62.
  156. Rowland K, Yeo WW, et al. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol. Br J Clin Pharmacol. 1994;38(1):9-14.
  157. Pellinen P, Honkakoski P, et al. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur J Pharmacol. 1994;270(1):35-43.
  158. Murray M, Butler AM, Stupans I. Competitive inhibition of human liver microsomal cytochrome P450 3A dependent steroid 6 beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro. J Pharmacol & Exp Therapeutics. 1994;270(2):645-9.
  159. Meschter CL, Mico BA, et al. A 13-week toxicologic and pathologic evaluation of prolonged cytochromes P450 inhibition by 1-aminobenzotriazole in male rats. Fundamental & Applied Toxicol. 1994;22(3):369-81.
  160. Leemann T, Bonnabry P, Dayer P. Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide. Life Sci. 1994;54(14):951-6.
  161. Bornheim LM, Everhart ET, et al. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol. 1993;45(6):1323-31.
  162. Wu D, Otton SV, et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol. 1993;35(1):30-4.
  163. LaBella FS, Queen G. General anesthetics inhibit cytochrome P450 monooxygenases and arachidonic acid metabolism. Can J Physiol & Pharmacol. 1993;71(1):48-53.
  164. Strobl GR, von Kruedener S, et al. Development of a pharmacophore for inhibition of human liver cytochrome P450 2D6: molecular modeling and inhibition studies. J Medicinal Chem. 1993;36(9):1136-45.
  165. Le Guellec C, Lacerelle B, et al. Inhibitory effects of anticancer drugs on dextromethorphan O-demethylase activity in human liver microsomes. Cancer Chemotherapy & Pharmacology. 1993;32(6):491-5.
  166. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol. 1992;34(3):256-61.
  167. Crewe HK, Lennard MS, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34(3):262-5.
  168. Hollander D, Pradas J, et al. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. Ann Neurol. 1994;36(6):920-4.
  169. Elliott K, Hynansky A, Inturrisi CE. Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain. 1994;59(3):361-8.
  170. Koymans LM, Vermeulen NP, et al. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J Computer Aided Mol Design. 1993;7(3):281-9.
  171. Fischer V, Vogels B, et al. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol & Exp Therapeutics. 1992;260(3):1355-60.
  172. Masimirembwa CM, Hasler JA, et al. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol. 1995;48(1):35-8.
  173. Fix AS, Wightman KA, O'Callaghan JP. Reactive gliosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex: GFAP evaluation by sandwich ELISA and immunocytochemistry. Neurotoxicol.. 1995;16(2):229-37.
  174. Fix AS, Wozniak DF, et al. Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex. Brain Res.. 1995 Oct 23;696(1-2):194-204.
  175. Farber NB, Foster J, et al. alpha-2 adrenergic agonists prevent MK-801 neurotoxicity. Neuropsychopharmacology. 1995 Jul;12(4):347-9.
  176. Feinberg I, Campbell IG, Marrs JC. Intraperitoneal dizocilpine induces cortical spike-wave seizure discharges in rats. Neuroscience Letters. 1995 Aug 25;196(3):157-60.
  177. Hargreaves RJ, Hill RG, Iversen LL. Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology [Review]. Acta Neurochirurgica - Supplementum. 1994;60:15-9.
  178. Martin P, Svensson A, et al. On the roles of dopamine D-1 vs. D-2 receptors for the hyperactivity response elicited by MK-801. J. Neural Transmission. 1994;95(2):113-21.
  179. Freeman JK, Goldberg MP. Confocal microscopic visualization of MK-801-induced cytoplasmic vacuoles in vitro. Psychopharmacology Bulletin. 1994;30(4):541-7.
  180. Jaatinen P, Kiianmaa K, et al. Ethanol-induced vacuolation in rat peripheral nervous system. J. Autonomic Nervous Sys. 1994 Jan-Feb;46(1-2):107-21.
  181. Cubells JF, Rayport S, et al. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine dependent intracellular oxidative stress. J. Neurosci.. 1994 Apr;14(4):2260-71.
  182. Auer RN, Coulter KC. The nature and time course of neuronal vacuolation induced by the N-methyl-D-aspartate antagonist MK-801. Acta Neuropathologica. 1994;87(1):1-7.
  183. Kilander K, Williams H. Yohimbine reduces neuropathology induced by ketamine/xylazine anesthesia. Physiology & Behavior. 1992 Mar;51(3):657-9.
  184. Sury MR. Genital examination under ketamine sedation in cases of suspected sexual abuse [letter; comment]. Archives of Disease in Childhood. 1994 Nov;71(5):481.
  185. Rogers R, Murdoch LJ. Genital examination under ketamine sedation in cases of suspected sexual abuse [letter; comment]. Archives of Disease in Childhood. 1994 Nov;71(5):481-482.
  186. Harari MD, Netzer D. Genital examination under ketamine sedation in cases of suspected sexual abuse. Archives of Disease in Childhood. 1994 Mar;70(3):197-9.
  187. Felser JM, Orban DJ. Dystonic reaction after ketamine abuse. Ann. Emerg. Med.. 1982 Dec;11(12):673-5.
  188. Ahmed SN, Petchovsky L. Abuse of ketamine [letter]. Brit. J. Psychiatry. 1980 Sep;137:303.
  189. Anonymous. Ketamine abuse. FDA Drug Bull.. 1979 Sep;9(4):24.
  190. Haigh JC. Use and abuse of drugs for chemical restraint of wildlife. Vet. Clinics of N. Am.. 1978 May;8(2):343-52.
  191. Cosgrove J, Newell TG. Recovery of neuropsychological functions during reduction in use of phencyclidine. J. Clin. Psychol.. 1991 Jan;47(1):159-69.
  192. Thombs DL. A review of PCP abuse trends and perceptions. [Review]. Public Health Reports. 1989 Jul-Aug;104(4):325-8.
  193. McCardle L, Fishein DH. The self-reported effects of PCP on human aggression. Addictive Behav.. 1989;14(4):465-72.
  194. Gorelick DA, Wilkins JN, Wong C. Outpatient treatment of PCP abusers. Am. J. Drug & Alcohol Abuse. 1989;15(4):367-74.
  195. Wright HH, Cole EA, et al. Phencyclidine-induced psychosis: eight-year follow-up of ten cases. S. Med. J.. 1988 May;81(5):565-7.
  196. Lue LP, Scimeca JA, et al. Pyrolitic fate of piperidinocyclohexanecarbonitrile, a contaminant of phencyclidine, during smoking. J. Analytical Toxicol.. 1988 Mar-Apr;12(2):57-61.
  197. Giannini AJ, Loiselle RH, et al. Augmentation of haloperidol by ascorbic acid in phencyclidine intoxication. Am. J. Psychiatry. 1987 Sep;144(9):1207-9.
  198. Golden NL, Kuhnert BR, et al. Neonatal manifestations of maternal phencyclidine exposure. J. Perinatal Med.. 1987;15(2):185-91.
  199. Foster HM, Narasimhachari N. Phencyclidine in CSF and serum: a case of attempted filicide by a mother without a history of substance abuse. J. Clin. Psychiatry. 1986 Aug;47(8):428-9.
  200. Rosen AM, Mukherjee S, Shinbach K. The efficacy of ECT in phencyclidine-induced psychosis. J. Clin. Psychiatry. 1984 May;45(5):220-2.
  201. Jacob MS, Carlen PL, et al. Phencyclidine ingestion: drug abuse and psychosis. Int. J. Addictions. 1981 May;16(4):749-58..
  202. Graeven DB, Sharp JG. Initiation, motivation, and cessation of phencyclidine use. J. Psychol.. 1981 May;108(1):43-57.
  203. Graeven DB, Sharp JG, Glatt S. Acute effects of phencyclidine (PCP) on chronic and recreational users. Am. J. Drug & Alcohol Abuse. 1981;8(1):39-50.
  204. Hadjiconstantinou M, Rossetti ZL, et al. Dizocilpine enhances striatal tyrosine hydroxylase and aromatic L-amino acid decarboxylase activity. Eur. J. Pharmacol.. 1995 Mar 15;289(1):97-101.
  205. Lannes B, Bernard V, et al. Chronic treatment with dizocilpine maleate increases the number of striatal neurons expressing the D2 receptor gene. Neurosci.. 1995 Mar;65(2):431-8.
  206. Patel TR, McCulloch J. AMPA receptor antagonism attenuates MK-801-induced hypermetabolism in the posterior cingulate cortex. Brain Res.. 1995 Jul 24;686(2):254-8.
  207. Riepe MW, Hori N, et al. Failure of neuronal ion exchange, not potentiated excitation, causes excitotoxicity after inhibition of oxidative phosphorylation. Neuroscience. 1995 Jan;64(1):91-7.
  208. Papp M, Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Phrmacol.. 1994 Sep 22;263(1-2):1-7.
  209. Ogren SO, Goldstein M. Phencyclidine- and dizocipline-induced hyperlocomotion are differentially mediated. Neuropsychopharmacol.. 1994 Nov;11(3):167-77.
  210. Kinoshita H, Hasegawa T, et al. Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice. Neurosci. Let.. 1994 Jun 6;174(1):101-4.
  211. Itzhak Y. Modulation of the PCP/NMDA receptor complex and sigma binding sites by psychostimulants. Neurotoxicol. & Teratol.. 1994 Jul-Aug;16(4):363-8.
  212. Klimek V, Papp M. The effect of MK-801 and imipramine on beta-adrenergic and 5HT2 receptors in the chronic mild stress model of depression in rats. Polish J. Pharmacol. 1994 Jan-Apr;46(1-2):67-9.
  213. Ellison G. Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport. 1994 Dec 20;5(18):2688-92.
  214. Thorat SN, Bhargava HN. Effects of NMDA receptor blockade and nitric oxide synthase inhibition on the acute and chronic actions of delta 9-tetrahydrocannabinol in rats. 77-82. 1994 Dec 19;667(1)
  215. Wessinger WD. Tolerance to and dependence on MK-801 (dizocilpine) in rats. Pharmacol., Biochem. & Behav.. 1994 Dec;49(4):1049-56.
  216. Brouillet E, Henshaw DR, et al. Aminooxyacetic acid striatal lesions attenuated by 1,3-butanediol and coenzyme Q10. Neurosci. Lett.. 1994 Aug 15;177(1-2):58-62.
  217. Fix AS, Horn JW, et al. Neuronal vacuole formation in the rat posterior cingulate/retrosplenial cortex after treatment with the N-methyl-D-aspartate (NMDA) antagonist MK-801 (dizocilpine maleate). Acta Neurophatologica. 1994;88(6):511-9.
  218. Mailleux P, Vanderhaeghen JJ. Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen. Eur. J. Pharmacol.. 1994 Jan 15;226(2):193-6.
  219. Berger P, Farrel K, et al. Drugs acting at the strychnine-insensitive glycine receptor do not induce HSP-70 protein in the cingulate cortex. Neurosci. Lett.. 1994 Feb 28;168(1-2):147-50.
  220. Vornov JJ, Tasker RC, Coyle JT. Delayed protection by MK-801 and tetrodotoxin in a rat organotypic hippocampal culture model of ischemia. Stroke. 1994 Feb;25(2):457-64.
  221. Gauer F, Masson-Pevet M, Pevet P. The NMDA antagonist MK-801 blocks light effect on melatonin receptor density in rat suprachiasmatic nuclei. Neurosci. Lett.. 1994 Apr 25;171(1-2):24-6.
  222. Akunne HC, Monn JA, et al. An electrophilic affinity ligand based on (+)-MK801 distinguishes PCP site 1 from PCP site 2. Neurochemical Res.. 1994 Apr;19(4):385-9.
  223. Papp M, Moryl E. New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. Polish J. Pharmacol.. 1993 Sep-Dec;45(5-6):549-53..
  224. Sun X, Larson AA. MK-801 inhibits the effects of capsaicin in the adult mouse by an action involving phencyclidine (PCP) sites not linked to NMDA activity. Neuroreport. 1993 Sep 3;4(10):1147-50.
  225. Panconi E, Roux J, et al. MK-801 and enantiomers: potential antidepressants or false positives in classical screening models?. Pharmacol., Biochem. & Behav.. 1993 Sep;46(1):15-20.
  226. Wedzony K, Golembiowska K. Concomitant administration of MK-801 and desipramine enhances extracellular concentration of dopamine in the rat prefrontal cortex. Neuroreport. 1993 Oct 25;5(1):75-7.
  227. Wedzony K, Golembiowska K, Klimek V. MK-801-induced symptoms of sensitization. The lack of correlation with the extracellular concentration of dopamine in the rat prefrontal cortex. Brain Res.. 1993 Oct 22;625(2):333-6.
  228. Layer RT, Bland LR, Skolnick P. MK-801, but not drugs acting at strychnine-insensitive glycine receptors, attenuate methamphetamine nigrostriatal toxicity. Brain Res.. 1993 Oct 15;625(1):38-44.
  229. Meloni D, Gambarana C, et al. Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol., Biochem. & Behav.. 1993 Oct;46(2):423-6.
  230. Rea MA, Buckley B, Lutton LM. Local administration of EAA antagonists blocks light-induced phase shifts and c-fos expression in hamster SCN. Am. J. Phsyiol.. 1993 Nov;265(5 pt 2):1191-8.
  231. Agnew WF, McCreeny DB, et al. MK-801 protects against neuronal injury induced by electrical stimulation. Neurosci.. 1993 Jan;52(1):45-53.
  232. Wu PH, Mihic SJ, et al. Blockade of chronic tolerance to ethanol by the NMDA antagonist, (+)-MK-801. Eur. J. Pharmacol.. 1993 Feb 9;231(2):157-64.
  233. Magnusson KR, Cotman CW. Effects of aging on NMDA and MK801 binding sites in mice. Brain Res.. 1993 Feb 26;604(1-2):334-7.
  234. Wieraszko A, Ball GF. Long-term potentiation in the avian hippocampus does not require activation of the N-methyl-D-aspartate (NMDA) receptor. Synapse. 1993 Feb;13(2):173-8.
  235. Akinci MK, Johnston GA. Sex differences in acute swim stress-induced changes in the binding of MK-801 to the NMDA subclass of glutamate receptors in mouse forebrain. J. Neurochem.. 1993 Dec;61(6):2290-3.
  236. Carlezon WA Jr, Wise RA. Morphine-induced potentiation of brain stimulation reward is enhanced by MK-801. Brain Res.. 1993 Aug 27;620(2):339-42.
  237. O'Donoghue DL, Poff CR, Block JJ. Chronic neonatal N-methyl-D-aspartate receptor antagonism with MK-801 increases the number of corticospinal cells retained into adulthood in the rat. Neurosci. Lett.. 1993 Aug 20;158(2):143-6.
  238. Ben-Eliyahu S, Page GG, et al. The NMDA receptor antagonist MK-801 blocks nonopioid stress induced analgesia and decreases tumor metastasis in the rat. Proceed. Western Pharmacol. Soc.. 1993;36:293-8.
  239. Hoffman DC, Donovan H, Cassella JV. The effects of haoperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacol.. 1993;111(3):339-44.
  240. Kasparov SA, Chizh BA. The NMDA-receptor antagonist dizocilpine (MK-801) suppresses the memory facilitatory action of thyrotropin-releasing hormone. Neuropeptides. 1992 Oct;23(2):87-92.
  241. Farfel GM, Vosmer GL, Seiden LS. The N-methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine and p-chloroamphetamine. Brain Res.. 1992 Nov 6;595(1):121-7.
  242. Simon DK, Prusky GT, O'Leary DD. N-methyl-D-aspartate receptor antagonists disrupt the formation of a mammalian neural map. Proceedings of the National Acadamy of Sciences of the United States of America. 1992 Nov 15;89(22):10593-7.
  243. Tasker RC, Coyle JT, Vornov JJ. The regional vulnerability to hypoglycemia-induced neurotoxicity in organotypic hippocampal culture: protection by early tetrodotoxin or delayed MK-801. J. Neurosci.. 1992 Nov;22(11):4298-308.
  244. Gandolfi O, Rimondini R, Dall'Olio R. The modulation of dopaminergic transmission in the striatum by MK-801 is independent of presynaptic mechanisms. Neuropharmacol.. 1992 Nov;31(11):1111-4.
  245. Maj J, Rogoz Z, Skuza G. The effects of combined treatment with MK-801 and antidepressant drugs in the forced swimming test in rats. Polish J. Pharmacol & Pharmacy. 1992 May-Jun;44(3):217-26.
  246. Gorter JA, de Bruin JP. Chronic neonatal MK-801 treatment results in an impairment of spatial learning in the adult rat. Brain Res.. 1992 May 15;580(1-2):12-7.
  247. De Montis MG, Devoto P, et al. NMDA receptor inhibition prevents tolerance to cocaine. Pharmacol., Biochem. & Behav.. 1992 May;42(1):179-82.
  248. Ben-Eliyahu S, Marek P, et al. The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res.. 1992 Mar 20;575(2):304-8.
  249. Shoaib M, Stolerman IP. MK-801 attenuates behavioural adaptation to chronic nicotine administration in rats. Brit. J. Pharmacol.. 1992 Mar;105(3):514-5.
  250. Maj J, Rogoz Z, et al. Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur. Neuropharmacol.. 1992 Mar;2(1):37-41.
  251. Shapiro ML, O'Connor C. N-methyl-D-aspartate receptor antagonist MK-801 and spatial memory representation: working memory is impaired in an unfamiliar environment but not in a familiar environment. Behav. Neurosci.. 1992 Aug;106(4):604-12.
  252. Whitton PS, Biggs CS, et al. MK-801 increases extracellular 5-hydroxytryptamine in rat hippocampus and striatum in vivo. J. Neurochem.. 1992 Apr;58(4):1573-5.
  253. Behrens S, Gattaz WF. MK-801 induced stereotypies in rats are decreased by haloperidol and increased by diazepam. J. Neural Transmission. 1992;90(3):219-24.
  254. Higgins GA, Nguyen P, Sellers EM. The NMDA antagonist dizocilpine (MK-801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. Life Sci.. 1992;50(21):PL167-72.
  255. Murase S, Nisell M, et al. Decreased sensory responsiveness of noradrenergic neurons in the rat locus coeruleus following phencyclidine or dizocilpine (MK-801): role of NMDA antagonism. Psychopharmacol.. 1992;109(3):271-6.
  256. Steardo L, Monteleone P, d'Istria M, Serino I, Maj M, Cuomo V. Sigma receptor modulation of noradrenergic-stimulated pineal melatonin biosynthesis in rats. Journal of Neurochemistry. 1996 Jul;67(1):287-93.
  257. Whitlock BB, Liu Y, Chang S, Saini P, Ha BK, Barrett TW, Wolfe SA Jr. Initial characterization and autoradiographic localization of a novel sigma/opioid binding site in immune tissues. Journal of Neuroimmunology. 1996 Jul;67(2):83-96.
  258. Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. Journal of Neuroscience. 1996 Feb 1;16(3):1193-202.
  259. Debonnel G, Bergeron R, Monnet FP, De Montigny C. Differential effects of sigma ligands on the N-methyl-D-aspartate response in the CA1 and CA3 regions of the dorsal hippocampus: effect of mossy fiber lesioning. Neuroscience. 1996 Apr;71(4):977-87.
  260. Debonnel G, de Montigny C. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. [Review]. Life Sciences. 1996;58(9):721-34.
  261. Samovilova NN, Prokazova NV. [Search for an endogenous ligand for sigma receptors]. [RUSSIAN]. Voprosy Meditsinskoi Khimii. 1995 Sep-Oct;41(5):9-13.
  262. Wyrick SD, Booth RG, Myers AM, Owens CE, Bucholtz EC, Hooper PC, Kula NS, Baldessarini RJ, Mailman RB. 1-Phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes and related derivatives as ligands for the neuromodulatory sigma 3 receptor: further structure-activity relationships. Journal of Medicinal Chemistry. 1995 Sep 15;38(19):3857-64.
  263. Carayon P, Bouaboula M, Loubet JF, Bourrie B, Petitpretre G, Le Fur G, Casellas P. The sigma ligand SR 31747 prevents the development of acute graft-versus-host disease in mice by blocking IFN-gamma and GM-CSF mRNA expression. International Journal of Immunopharmacology. 1995 Sep;17(9):753-61.
  264. Gudelsky GA. Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. European Journal of Pharmacology. 1995 Nov 24;286(3):223-8.
  265. Bertha CM, Vilner BJ, Mattson MV, Bowen WD, Becketts K, Xu H, Rothman RB, Flippen-Anderson JL, Rice KC. (E)-8-benzylidene derivatives of 2-methyl-5-(3-hydroxyphenyl)morphans: highly selective ligands for the sigma 2 receptor subtype. Journal of Medicinal Chemistry. 1995 Nov 24;38(24):4776-85.
  266. Steardo L, Monteleone P, d'Istria M, Serino I, Maj M, Cuomo V. (+)-N-allylnormetazocine enhances N-acetyltransferase activity and melatonin synthesis: preliminary evidence for a functional role of sigma receptors in the rat pineal gland. Journal of Pharmacology & Experimental Therapeutics. 1995 Nov;275(2):845-9.
  267. Chien CC, Pasternak GW. Sigma antagonists potentiate opioid analgesia in rats. Neuroscience Letters. 1995 May 5;190(2):137-9.
  268. Bowen WD, Bertha CM, Vilner BJ, Rice KC. CB-64D and CB-184: ligands with high sigma 2 receptor affinity and subtype selectivity. European Journal of Pharmacology. 1995 May 24;278(3):257-60.
  269. Brent PJ, Pang GT. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. European Journal of Pharmacology. 1995 May 15;278(2):151-60.
  270. Schoenwald RD, Barfknecht CF, Shirolkar S, Xia E. The effects of sigma ligands on protein release from lacrimal acinar cells: a potential agonist/antagonist assay. Life Sciences. 1995 Mar 3;56(15):1275-85.
  271. Bergeron R, de Montigny C, Debonnel G. Biphasic effects of sigma ligands on the neuronal response to N-methyl-D-aspartate. Naunyn-Schmiedebergs Archives of Pharmacology. 1995 Mar;351(3):252-60.
  272. Bastianetto S, Rouquier L, Perrault G, Sanger DJ. DTG-induced circling behaviour in rats may involve the interaction between sigma sites and nigro-striatal dopaminergic pathways. Neuropharmacology. 1995 Mar;34(3):281-7.
  273. Bowen WD, Vilner BJ, Williams W, Bertha CM, Kuehne ME, Jacobson AE. Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity. European Journal of Pharmacology. 1995 Jun 6;279(1):R1-3.
  274. Liu Y, Whitlock BB, et al. Sigma-1 receptors modulate functional activity of rat splenocytes. J. Neuroimmunology. 1995 Jun;59(1-2):143-54.
  275. Yamamoto H, Yamamoto T, Sagi N, Klenerova V, Goji K, Kawai N, Baba A, Takamori E, Moroji T. Sigma ligands indirectly modulate the NMDA receptor-ion channel complex on intact neuronal cells via sigma 1 site. Journal of Neuroscience. 1995 Jan;15(1 Pt 2):731-6.
  276. Gonzalez-Alvear GM, Werling LL. Sigma receptor regulation of norepinephrine release from rat hippocampal slices. Brain Research. 1995 Feb 27;673(1):61-9.
  277. Weiser SD, Patrick SL, Mascarella SW, Downing-Park J, Bai X, Carroll FI, Walker JM, Patrick RL. Stimulation of rat striatal tyrosine hydroxylase activity following intranigral administration of sigma receptor ligands. European Journal of Pharmacology. 1995 Feb 24;275(1):1-7.
  278. Kreeger JS, Yukhananov RYu, Larson AA. Altered N-methyl-D-aspartate (NMDA) activity in the mouse spinal cord following morphine is mediated by sigma activity. Brain Research. 1995 Feb 20;672(1-2):83-8.
  279. Church J, Fletcher EJ. Blockade by sigma site ligands of high voltage-activated Ca2+ channels in rat and mouse cultured hippocampal pyramidal neurones. British Journal of Pharmacology. 1995 Dec;116(7):2801-10.
  280. Fletcher EJ, Church J, Abdel-Hamid K, MacDonald JF. Blockade by sigma site ligands of N-methyl-D-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurones. British Journal of Pharmacology. 1995 Dec;116(7):2791-800.
  281. Gonzalez-Alvear GM, Thompson-Montgomery D, Deben SE, Werling LL. Functional and binding properties of sigma receptors in rat cerebellum. Journal of Neurochemistry. 1995 Dec;65(6):2509-16.
  282. Kest B, Mogil JS, Sternberg WF, Pechnick RN, Liebeskind JC. Antinociception following 1,3,-di-o-tolylguanidine, a selective sigma receptor ligand. Pharmacology, Biochemistry & Behavior. 1995 Apr;50(4):587-92.
  283. Mach RH, Smith CR, Childers SR. Ibogaine possesses a selective affinity for sigma 2 receptors. Life Sciences. 1995;57(4):PL57-62.
  284. Pechnick RN, Poland RE. Neuroendocrine responses produced by enantiomeric pairs of drugs that interact with phencyclidine and sigma receptors. European Journal of Pharmacology. 1994 Sep 22;263(1-2):115-20.
  285. Bonhaus DW, Loury DN, et al. [3H]RS-23597-190, a potent 5-hydroxytryptamine4 antagonist labels sigma-1 but not sigma-2 binding sites in guinea pig brain. J. Pharmacol. & Exp. Therapeutics. 1994 Oct;271(1):484-93.
  286. Nyberg L, McIntosh AR, Cabeza R, Nilsson LG, Houle S, Habib R, Tulving E. Network analysis of positron emission tomography regional cerebral blood flow data: ensemble inhibition during episodic memory retrieval. Journal of Neuroscience. 1996 Jun 1;16(11):3753-9.
  287. Ho AP, Gillin JC, Buchsbaum MS, Wu JC, Abel L, Bunney WE Jr. Brain glucose metabolism during non-rapid eye movement sleep in major depression. A positron emission tomography study. Archives of General Psychiatry. 1996 Jul;53(7):645-52.
  288. Gyulai FE, Firestone LL, Mintun MA, Winter PM. In vivo imaging of human limbic responses to nitrous oxide inhalation. Anesthesia & Analgesia. 1996 Aug;83(2):291-8.
  289. Fix AS, Wightman KA, O'Callaghan JP. Reactive gliosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex: GFAP evaluation by sandwich ELISA and immunocytochemistry. Neurotoxicology. 1995 Summer;16(2):229-37.
  290. Fix AS, Wozniak DF, Truex LL, McEwen M, Miller JP, Olney JW. Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex. Brain Research. 1995 Oct 23;696(1-2):194-204.
  291. Noga JT, Aylward E, Barta PE, Pearlson GD. Cingulate gyrus in schizophrenic patients and normal volunteers. Psychiatry Research. 1995 Nov 10;61(4):201-8.
  292. Fletcher PC, Happe F, Frith U, Baker SC, Dolan RJ, Frackowiak RS, Frith CD. Other minds in the brain: a functional imaging study of "theory of mind" in story comprehension. Cognition. 1995 Nov;57(2):109-28.
  293. Flugge G. Dynamics of central nervous 5-HT1A-receptors under psychosocial stress. Journal of Neuroscience. 1995 Nov;15(11):7132-40.
  294. Yukie M. Neural connections of auditory association cortex with the posterior cingulate cortex in the monkey. Neuroscience Research. 1995 May;22(2):179-87.
  295. Stanton GB, Bruce CJ, Goldberg ME. Topography of projections to posterior cortical areas from the macaque frontal eye fields. Journal of Comparative Neurology. 1995 Mar 6;353(2):291-305.
  296. Ishimaru M, Fukamauchi F, Olney JW. Halothane prevents MK-801 neurotoxicity in the rat cingulate cortex. Neuroscience Letters. 1995 Jun 23;193(1):1-4.
  297. Sharp JW, Petersen DL, Langford MT. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Research. 1995 Jul 31;687(1-2):114-24.
  298. Hedberg TG, Stanton PK. Long-term potentiation and depression of synaptic transmission in rat posterior cingulate cortex. Brain Research. 1995 Jan 30;670(2):181-96.
  299. Fredrikson M, WIk G, Annas P, Ericson K, Stone-Elander S. Functional neuroanatomy of visually elicited simple phobic fear: additional data and theoretical analysis. Psychophysiology. 1995 Jan;32(1):43-8.
  300. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. [Review]. Brain Research - Brain Research Reviews. 1995 Feb;20(2):250-67.
  301. Izumisawa N, Kawakami A, Ohata T, Hanada T, Okeda R. YM90K, an AMPA antagonist, has no neurotoxic effects on cerebrocortical neurons in rats. Experimental Neurology. 1995 Aug;134(2):199-204.
  302. Sharp FR, Butman M, Koistinaho J, Aardalen K, Nakki R, Massa SM, Swanson RA, Sagar SM. Phencyclidine induction of the hsp 70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience. 1994 Oct;62(4):1079-92.
  303. Bottini G, Corcoran R, Sterzi R, Paulesu E, Schenone P, Scarpa P, Frackowiak RS, Frith CD. The role of the right hemisphere in the interpretation of figurative aspects of language. A positron emission tomography activation study. Brain. 1994 Dec;117 ( Pt 6):1241-53.
  304. Molchan SE, Sunderland T, McIntosh AR, Herscovitch P, Schreurs BG. A functional anatomical study of associative learning in humans. Proceedings of the National Academy of Sciences of the United States of America. 1994 Aug 16;91(17):8122-6.
  305. McGuire PK, Bench CJ, Frith CD, Marks IM, Frackowiak RS, Dolan RJ. Functional anatomy of obsessive-compulsive phenomena. British Journal of Psychiatry. 1994 Apr;164(4):459-68.
  306. Hargreaves RJ, Hill RG, Iversen LL. Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. [Review]. Acta Neurochirurgica - Supplementum. 1994;60:15-9.
  307. Auer RN, Coulter KC. The nature and time course of neuronal vacuolation induced by the N-methyl-D-aspartate antagonist MK-801. Acta Neuropathologica. 1994;87(1):1-7.
  308. Fix AS, Horn JW, Truex LL, Smith RA, Gomez E. Neuronal vacuole formation in the rat posterior cingulate/retrosplenial cortex after treatment with the N-methyl-D-aspartate (NMDA) antagonist MK-801 (dizocilpine maleate). Acta Neuropathologica. 1994;88(6):511-9.
  309. Fix AS. Pathological effects of MK-801 in the rat posterior cingulate/retrosplenial cortex. [Review]. Psychopharmacology Bulletin. 1994;30(4):577-83.
  310. Schlaug G, Armstrong E, Schleicher A, Zilles K. Layer V pyramidal cells in the adult human cingulate cortex. A quantitative Golgi-study. Anatomy & Embryology. 1993 Jun;187(6):515-22.
  311. Hedberg TG, Simpson GV, Stanton PK. Microcircuitry of posterior cingulate cortex in vitro: electrophysiology and laminar analysis using the current source density method [published erratum appears in Brain Res 1994 May 30;647(1):177-9]. Brain Research. 1993 Dec 31;632(1-2):239-48.
  312. Hargreaves RJ, Rigby M, Smith D, Hill RG, Iversen LL. Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochemical Research. 1993 Dec;18(12):1263-9.
  313. Bench CJ, Friston KJ, Brown RG, Frackowiak RS, Dolan RJ. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. [Review]. Psychological Medicine. 1993 Aug;23(3):579-90.
  314. Hof PR, Archin N, Osmand AP, Dougherty JH, Wells C, Bouras C, Morrison JH. Posterior cortical atrophy in Alzheimer's disease: analysis of a new case and re-evaluation of a historical report. Acta Neuropathologica. 1993;86(3):215-23.
  315. Olson CR, Musil SY. Topographic organization of cortical and subcortical projections to posterior cingulate cortex in the cat: evidence for somatic, ocular, and complex subregions. Journal of Comparative Neurology. 1992 Oct 8;324(2):237-60.
  316. Olson CR, Musil SY. Posterior cingulate cortex: sensory and oculomotor properties of single neurons in behaving cat. Cerebral Cortex. 1992 Nov-Dec;2(6):485-502.
  317. Vogt BA, Crino PB, Vogt LJ. Reorganization of cingulate cortex in Alzheimer's disease: neuron loss, neuritic plaques, and muscarinic receptor binding. Cerebral Cortex. 1992 Nov-Dec;2(6):526-35.
  318. Duval D, Roome N, Gauffeny C, Nowicki JP, Scatton B. SL 82.0715, an NMDA antagonist acting at the polyamine site, does not induce neurotoxic effects on rat cortical neurons. Neuroscience Letters. 1992 Mar 30;137(2):193-7.
  319. Neave N, Lloyd S, Sahgal A, Aggleton JP. Lack of effect of lesions in the anterior cingulate cortex and retrosplenial cortex on certain tests of spatial memory in the rat. Behavioural Brain Research. 1994 Nov 16;65(1):89-101.
  320. Gage SL, Keim SR, Simon JR, Low WC. Cholinergic innervation of the retrosplenial cortex via the fornix pathway as determined by high affinity choline uptake, choline acetyltransferase activity, and muscarinic receptor binding in the rat. Neurochemical Research. 1994 Nov;19(11):1379-86.
  321. Tulving E, Markowitsch HJ, Kapur S, Habib R, Houle S. Novelty encoding networks in the human brain: positron emission tomography data. Neuroreport. 1994 Dec 20;5(18):2525-8.
  322. Gao XM, Shirakawa O, Du F, Tamminga CA. Delayed regional metabolic actions of phencyclidine. European Journal of Pharmacology. 1993 Sep 7;241(1):7-15.
  323. Fix AS, Horn JW, Wightman KA, Johnson CA, Long GG, Storts RW, Farber N, Wozniak DF, Olney JW. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Experimental Neurology. 1993 Oct;123(2):204-15.
  324. Wyss JM, Van Groen T. Connections between the retrosplenial cortex and the hippocampal formation in the rat: a review. [Review]. Hippocampus. 1992 Jan;2(1):1-11.
  325. Nakki R, Nickolenko J, Chang J, Sagar SM, Sharp FR. Haloperidol prevents ketamine- and phencyclidine-induced HSP70 protein expression but not microglial activation. Experimental Neurology. 1996 Feb;137(2):234-41.
  326. Verma A, Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. Journal of Neuroscience. 1996 Jan;16(1):373-9.
  327. Steinberg GK, Bell TE, Yenari MA. Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. Journal of Neurosurgery. 1996 May;84(5):860-6.
  328. Farber NB, Foster J, Duhan NL, Olney JW. alpha 2 adrenergic agonists prevent MK-801 neurotoxicity. Neuropsychopharmacology. 1995 Jul;12(4):347-9.
  329. Olney JW. Neurotoxicity of NMDA receptor antagonists: an overview. [Review]. Psychopharmacology Bulletin. 1994;30(4):533-40.
  330. Persinger MA, Psych C. Sudden unexpected death in epileptics following sudden, intense, increases in geomagnetic activity: prevalence of effect and potential mechanisms. International Journal of Biometeorology. 1995 May;38(4):180-7.
  331. Persinger MA. On the possibility of directly accessing every human brain by electromagnetic induction of fundamental algorithms. Perceptual & Motor Skills. 1995 Jun;80(3 Pt 1):791-9.
  332. Persinger MA, Richards PM. Vestibular experiences of humans during brief periods of partial sensory deprivation are enhanced when daily geomagnetic activity exceeds 15-20 nT. Neuroscience Letters. 1995 Jul 14;194(1-2):69-72.
  333. Persinger MA. Out-of-body-like experiences are more probable in people with elevated complex partial epileptic-like signs during periods of enhanced geomagnetic activity: a nonlinear effect. Perceptual & Motor Skills. 1995 Apr;80(2):563-9.
  334. Persinger MA. Complex partial epileptic-like signs contribute differential sources of variance to low self-esteem and imaginings. Perceptual & Motor Skills. 1995 Apr;80(2):427-31.
  335. Persinger MA, Bureau YR, Peredery OP, Richards PM. The sensed presence as right hemispheric intrusions into the left hemispheric awareness of self: an illustrative case study [see comments]. Perceptual & Motor Skills. 1994 Jun;78(3 Pt 1):999-1009.
  336. Persinger MA, Richards PM, Koren SA. Differential ratings of pleasantness following right and left hemispheric application of low energy magnetic fields that stimulate long-term potentiation. International Journal of Neuroscience. 1994 Dec;79(3-4):191-7.
  337. Tiller SG, Persinger MA. Enhanced hypnotizability by cerebrally applied magnetic fields depends upon the order of hemispheric presentation: an anistropic effect. International Journal of Neuroscience. 1994 Dec;79(3-4):157-63.
  338. Tiller SG, Persinger MA. Elevated incidence of a sensed presence and sexual arousal during partial sensory deprivation and sensitivity to hypnosis: implications for hemisphericity and gender differences. Perceptual & Motor Skills. 1994 Dec;79(3 Pt 2):1527-31.
  339. Persinger MA. Sense of a presence and suicidal ideation following traumatic brain injury: indications of right-hemispheric intrusions from neuropsychological profiles. Psychological Reports. 1994 Dec;75(3 Pt 1):1059-70.
  340. Johnson CP, Persinger MA. The sensed presence may be facilitated by interhemispheric intercalation: relative efficacy of the Mind's Eye, Hemi-Sync Tape, and bilateral temporal magnetic field stimulation. Perceptual & Motor Skills. 1994 Aug;79(1 Pt 1):351-4.
  341. Skirda RJ, Persinger MA. Positive associations among dichotic listening errors, complex partial epileptic-like signs, and paranormal beliefs [see comments]. Journal of Nervous & Mental Disease. 1993 Nov;181(11):663-7.
  342. Persinger MA. Vectorial cerebral hemisphericity as differential sources for the sensed presence, mystical experiences and religious conversions. [Review]. Perceptual & Motor Skills. 1993 Jun;76(3 Pt 1):915-30.
  343. Persinger MA, Makarec K. Complex partial epileptic signs as a continuum from normals to epileptics: normative data and clinical populations. Journal of Clinical Psychology. 1993 Jan;49(1):33-45.
  344. Persinger MA. Transcendental Meditation and general meditation are associated with enhanced complex partial epileptic-like signs: evidence for "cognitive" kindling?. Perceptual & Motor Skills. 1993 Feb;76(1):80-2.
  345. Dittburner TL, Persinger MA. Intensity of amnesia during hypnosis is positively correlated with estimated prevalence of sexual abuse and alien abductions: implications for the false memory syndrome. Perceptual & Motor Skills. 1993 Dec;77(3 Pt 1):895-8.
  346. Persinger MA. Geophysical variables and behavior: LXXI. Differential contribution of geomagnetic activity to paranormal experiences concerning death and crisis: an alternative to the ESP hypothesis. Perceptual & Motor Skills. 1993 Apr;76(2):555-62.
  347. Persinger MA. Average diurnal changes in melatonin levels are associated with hourly incidence of bereavement apparitions: support for the hypothesis of temporal (limbic) lobe microseizuring. Perceptual & Motor Skills. 1993 Apr;76(2):444-6.
  348. Persinger MA, Makarec K. The feeling of a presence and verbal meaningfulness in context of temporal lobe function: factor analytic verification of the muses?. Brain & Cognition. 1992 Nov;20(2):217-26.
  349. Persinger MA. Enhanced incidence of "the sensed presence" in people who have learned to meditate: support for the right hemispheric intrusion hypothesis. Perceptual & Motor Skills. 1992 Dec;75(3 Pt 2):1308-10.
  350. Jaynes J. The origin of consciousness in the breakdown of the bicameral mind. Houghton Mifflin. 1977 (Boston)
  351. Bayorh MA, McGee LJ. Cardiovascular and hemodynamic effects of acute and chronic phencyclidine (PCP). Res Comm Subs Abuse. 1989;10(1):27-36.
  352. Rosenberg J, Pentel P, Pond S, benowitz N, Olson K. Hyperthermia associated with drug intoxication. Crit Care Med. 1986;14(11):964-9.
  353. Hoogwerf B, Kern J, Bullock M, Comty CM. Phencyclidine-induced rhabdomyolysis and acute renal failure. Clin Toxicol. 1979;14(1):47-53.
  354. Dunn JR, Fuller M, Zoeger J, et al. Magnetic material in the human hippocampus. Brain Res Bull. 1995;36(2):149-53.
  355. Perry PJ, Alexander B, Ellingrod VL. http://www.vh.org/Providers/Conferences/CPS/29.html
  356. Crews DJ, Landers DM. Electroencephalographic measures of attentional patterns prior to the golf putt. Medicine & Science in Sports & Exercise. 1993 Jan;25(1):116-26.
  357. Steffensen SC. Dehydroepiandrosterone sulfate suppresses hippocampal recurrent inhibition and synchronizes neuronal activity to theta rhythm. Hippocampus. 1995;5(4):320-8.
  358. Thinschmidt JS, Kinney GG, Kocsis B. The supramammillary nucleus: is it necessary for the mediation of hippocampal theta rhythm?. Neuroscience. 1995 Jul;67(2):301-12.
  359. O'Keefe J. Hippocampus, theta, and spatial memory [Review]. Current Opinion in Neurobiology. 1993 Dec;3(6):917-24.
  360. Campbell IG, Feinberg I. Noncompetitive NMDA channel blockade during waking intensely stimulates NREM delta. Journal of Pharmacology & Experimental Therapeutics. 1996 Feb;276(2):737-42.
  361. Vallee J. Passport to Magonia (2nd ed). Contemporary Books. 1993 (Chicago)
  362. Perovic S, Pergande G, Ushijima H, et al. Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Neurodegeneration. 1995 Dec;4(4):369-74.
  363. Blin O, Azulay JP, Desnuelle C, et al. A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis. Clinical Neuropharmacology. 1996 Apr;19(2):189-92.
  364. Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am-J-Emerg-Med. 1994 Nov;12(6):642-4.
  365. Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome?. Pharmacopsychiatry. 1996 Jul;29(4):159-61.
  366. Bodner RA, Lynch T, Lewis L, Kahn-D. Serotonin syndrome. Neurology. 1995 Feb;45(2):219-23.
  367. Yoo Y, Chung H, Kim E, Kim M. Fatal zipeprol and dextromethorphan poisonings on Korea. J Analytical Toxicol. 1996 May-Jun;20(3):155-8.
  368. Suzuki T, Katto J, Saeki S, et al. Analgesic effect of dextromethorphan for postherpetic neuralgia [Japanese]. Masui - Japanese Journal of Anesthesiology. 1996 May;45(5):629-33.
  369. Benade JG. A massive outbreak of food poisoning -- a reminder of the importance of proper toxic waste control. South African Medical Journal. 1996 May;86(5):551-2.
  370. Foreman J. http://www.critpath.org/newsletters/wtp/0196/shingles.htm
  371. Anderson P. http://www.emergency.com/philher2.htm
  372. Anonymous. Scopolamine poisoning among heroin users -- New York City, Newark, Philadelphia, and Baltimore, 1995 and 1996. Morbidity & Mortality Weekly Report. 1996 Jun 7;45(22):457-60.
  373. Kauppila T, Gronroos M, Pertovaara A. An attempt to attenuate experimental pain in humans by dextromethorphan, an NMDA receptor antagonist. Pharmacology, Biochemistry & Behavior. 1995 Nov;52(3):641-4.
  374. Storrow AB, Magoon MR, Norton J. The dextromethorphan defense: dextromethorphan and the opioid screen. Academic Emergency Medicine. 1995 Sep;2(9):791-4.
  375. McQuay HJ, Carroll D, Jadad AR, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain. 1994 Oct;59(1):127-33.
  376. Puchetti V, Faccini GB, Micciolo R, et al. Dextromethorphan test for evaluation of congenital predisposition to lung cancer. Chest. 1994 Feb;105(2):449-53.
  377. . http://atlas.comet.net/~bigfun
  378. Fowler JS, Volkow ND, Wang GJ, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA. 1996 Nov 26;93(24):14065-9.
  379. Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers [see comments]. Nature. 1996 Feb 22;379(6567):733-6.